trending Market Intelligence /marketintelligence/en/news-insights/trending/nh0uycabdyh85hb7pb3hkw2 content esgSubNav
In This List

BerGenBio appoints CFO to accelerate cancer therapy development

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


BerGenBio appoints CFO to accelerate cancer therapy development

Bergen, Norway-based BerGenBio ASA appointed Rune Skeie as CFO.

Skeie was previously CFO of REMA Franchise Norge AS.

Skeie's experience in finance and corporate development will help BerGenBio as it advances its product pipeline, which includes bemcentinib, CEO Richard Godfrey said.

Bemcentinib is being studied in combination with other drugs for treating types of lung cancer, breast cancer and leukemia.